Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open Label Extension Study of the Efficacy of MORAb-003
NCT01018563 · Morphotek · PHASE2 · terminated · last registry update 2021-12-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated by sponsor due to futile results in NCT00849667 study.” | – | Registry record, Morphotek |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FOLR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-11-21Phase 3 first posted: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Mirvetuximab Soravtansine (NCT05622890)
- 2022-07-06Phase 3 first posted: AbbVie, Mirvetuximab soravtansine plus Bevacizumab + Bevacizumab (NCT05445778)
- 2021-09-30Also stopped (terminated): Endocyte, EC145 + Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) (NCT01170650)
- 2021-09-02Results posted on the registry: Eisai Inc., Farletuzumab + Placebo (NCT02289950)
- 2021-02-17Results posted on the registry: ImmunoGen, Inc., Mirvetuximab soravtansine (NCT01609556)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision